[Form 4] Utah Medical Products Inc Insider Trading Activity

Rhea-AI Filing Summary

Brian L. Koopman, Principal Financial Officer of Utah Medical Products Inc. (UTMD), reported the sale of 50 shares of the company's common stock on 09/04/2025 at a price of $62.75 per share. Following the reported transaction, Mr. Koopman beneficially owns 832 shares in a direct capacity. The Form 4 is signed by Mr. Koopman on 09/05/2025.

Insights

Securities Compliance Analyst

TL;DR: Routine insider sale disclosed timely; small size relative to typical insider holdings suggests non-material personal liquidity.

The filing shows a single non-derivative disposal of 50 shares by the Principal Financial Officer on 09/04/2025 at $62.75, with 832 shares remaining beneficially owned directly. From a compliance perspective the Form 4 provides required disclosure of the transaction and ownership level. The sale code reported is 'G', indicating a routine transaction under a Rule 10b5-1 trading plan or similar pre-arranged plan; the form includes the plan-code designation. No derivatives or amendments are reported.

Corporate Governance Specialist

TL;DR: Small, disclosed sale by an officer; recordkeeping and timely reporting appear in order.

The transaction is limited in size (50 shares) and the disclosure shows direct ownership of 832 shares after the sale. The report is filed individually by the reporting person and bears a manual signature dated 09/05/2025. There are no indications of material shifts in insider ownership or control. For governance stakeholders, this filing documents routine insider activity without material corporate governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koopman Brian

(Last) (First) (Middle)

108 E 1700 S

(Street)

BOUNTIFUL UT 84010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UTAH MEDICAL PRODUCTS INC [ UTMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		G		50	D	$62.75	832	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brian L. Koopman	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did UTMD CFO Brian Koopman report on Form 4?

The Form 4 reports a sale of 50 shares of Utah Medical Products Inc. common stock on 09/04/2025 at $62.75 per share.

How many UTMD shares does Brian Koopman own after the sale?

The filing states Mr. Koopman beneficially owns 832 shares directly following the reported transaction.

What is the reporting person’s role at UTMD?

Brian L. Koopman is identified as the company’s Principal Financial Officer on the Form 4.

Was the Form 4 filed on time and signed?

Yes. The Form 4 shows the signature of Brian L. Koopman dated 09/05/2025, indicating timely filing following the 09/04/2025 transaction.

Does the Form 4 show any derivative transactions or amendments?

No. The filing includes only a non-derivative sale of common stock and shows no derivatives or amendments.